# Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.

> **NCT06523231** · PHASE2 · COMPLETED · sponsor: **LimmaTech Biologics AG** · enrollment: 110 (actual)

## Conditions studied

- Shigellosis

## Interventions

- **BIOLOGICAL:** Shigella4V2
- **BIOLOGICAL:** MenACWY

## Key facts

- **NCT ID:** NCT06523231
- **Lead sponsor:** LimmaTech Biologics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-07
- **Primary completion:** 2025-08-27
- **Final completion:** 2026-01-22
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06523231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06523231, "Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06523231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*